Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 7/20 | 0.34 |
| ▸ | MTOR | P42345 | 6/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.33 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601693 | 0.87 | PIK3CD (0.33) | DGAT1SOAT1MTORPIK3CAPIK3CD | |
| SCHEMBL31601874 | 0.84 | DGAT1 (0.40) | DGAT1SOAT1MTORPIK3CDPIK3CG | |
| SCHEMBL31601853 | 0.74 | DGAT1 (0.40) | DGAT1SOAT1MTORPIK3CDPIK3CG | |
| SCHEMBL104174 | 0.74 | CDK9 (0.33) | — | |
| SCHEMBL10282480 | 0.74 | TTK (0.32) | MTORPIK3CAAKT1 | |
| SCHEMBL104889 | 0.73 | TTK (0.42) | — | |
| SCHEMBL31601880 | 0.72 | NR1D1 (0.34) | KMT2AL3MBTL1 | |
| SCHEMBL31601748 | 0.72 | NR1D1 (0.34) | L3MBTL1 | |
| SCHEMBL31602029 | 0.71 | THRB (0.39) | DGAT1SOAT1 | |
| SCHEMBL12927947 | 0.70 | TTK (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110815-A1 | IMIDAZO [1,2-B] PYRIDAZINE-BASED NOVEL COMPOUND AS CDK INHIBITOR AND USE THEREOF | 아이리드비엠에스 주식회사 | 2025-05-30 | — | — | WO | disclosed |